ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab

ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint 

See more here